Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors

Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David L. Bushnell, Thomas M. O'Dorisio, M. Sue O'Dorisio, Yusuf Menda, Jan Müller-Brand, James R. Howe, Thorvardur R. Halfdanarson

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Objectives: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). Methods: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. Results: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and themedian time to progressionwas 23.9months.Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. Conclusions: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalPancreas
Volume46
Issue number2
DOIs
StatePublished - Jan 1 2017

Keywords

  • Chromogranin A
  • Neuroendocrine tumors
  • PRRT
  • Pancreastatin
  • Peptide receptor radionuclide therapy
  • Therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors'. Together they form a unique fingerprint.

  • Cite this

    Sharma, N., Naraev, B. G., Engelman, E. G., Zimmerman, M. B., Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Müller-Brand, J., Howe, J. R., & Halfdanarson, T. R. (2017). Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas, 46(2), 151-156. https://doi.org/10.1097/MPA.0000000000000734